MedTrace Logo

CUTE (Chronic Urticaria Treatment Evaluation)

NCT00264303 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 886

Last updated 2011-08-31

Study results available
· View outcomes & findings →

Summary

A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment

Conditions

  • Chronic Idiopathic Urticaria

Interventions

DRUG

Levocetirizine

5mg oral capsules, once daily, 4 week duration

DRUG

Desloratadine

5mg oral capsules, once daily, 4 week duration

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Malaysia
  • Romania
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264303 on ClinicalTrials.gov